ArticleBlood cancer journal2012
Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche?
Article in Blood cancer journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 62 citations in OpenAlex.
- Lymphatic vascular aging and age-related bone loss: current status and future perspectives.Frontiers in immunology · 2026Review
- Expression ofInternational journal of molecular sciences · 2025Article
- Age-related mesenchymal stromal cell senescence is associated with progression from MGUS to multiple myeloma.Leukemia · 2025Article
- Myeloperoxidase creates a permissive microenvironmental niche for the progression of multiple myeloma.British journal of haematology · 2023Article
- Transcription ofGenes · 2023Article
- Simultaneously Targeting Two Coupled Signalling Molecules in the Mesenchymal Stem Cell Support Efficiently Sensitises the Multiple Myeloma Cell Line H929 to Bortezomib.International journal of molecular sciences · 2023Article
- Targeting CAM-DR and Mitochondrial Transfer for the Treatment of Multiple Myeloma.Current oncology (Toronto, Ont.) · 2022Review
- Calorie restriction has no effect on bone marrow tumour burden in a Vk*MYC transplant model of multiple myeloma.Scientific reports · 2022Article
- The Route of the Malignant Plasma Cell in Its Survival Niche: Exploring "Multiple Myelomas".Cancers · 2022Review
- The Burden of a Multiple Myeloma Diagnosis on Patients and Caregivers in the First Year: Western European Findings.ClinicoEconomics and outcomes research : CEOR · 2022Article
- Hematopoietic Multipotent Progenitors and Plasma Cells: Neighbors or Roommates in the Mouse Bone Marrow Ecosystem?Frontiers in immunology · 2021Review
- Tumour Dissemination in Multiple Myeloma Disease Progression and Relapse: A Potential Therapeutic Target in High-Risk Myeloma.Cancers · 2020Review
- [The effect of peripheral blood cell score on the prognosis of multiple myeloma patients treated with bortezomib].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020Article
- Bone Marrow Gouty Tophi With Plasma Cell Myeloma.Annals of laboratory medicine · 2020Article
- Engineering a Humanised Niche to Support Human Haematopoiesis in Mice: Novel Opportunities in Modelling Cancer.Cancers · 2020Article
- Multiple Myeloma as a Bone Disease? The Tissue Disruption-Induced Cell Stochasticity (TiDiS) Theory.Cancers · 2020Article
- Targeted Disruption of Bone Marrow Stromal Cell-Derived Gremlin1 Limits Multiple Myeloma Disease Progression In Vivo.Cancers · 2020Article
- LCRF-0006, a small molecule mimetic of the N-cadherin antagonist peptide ADH-1, synergistically increases multiple myeloma response to bortezomib.FASEB bioAdvances · 2020Article
- Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients.American journal of hematology · 2020Article
- Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo.Neoplasia (New York, N.Y.) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the adult mammal, normal haematopoiesis occurs predominantly in the bone marrow, where primitive haematopoietic stem cells (HSC) and their progeny reside in specialised microenvironments. The bone marrow microenvironment contains specific anatomical areas (termed niches) that are highly specialised for the development of certain blood cell types, for example HSCs. The HSC niche provides important cell-cell interactions and signalling molecules that regulate HSC self-renewal and differentiation processes. These same signals and interactions are also important in the progression of haematological malignancies, such as multiple myeloma (MM). This review provides an overview of the bone marrow microenvironment and its involvement in normal, physiological HSC maintenance and plasma cell growth throughout MM disease progression.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.